Evidence map›Paper›PMID 40733741›Full record

ArticleVaccines2025

mRNA-LNP Vaccines Targeting SmpA-PLD and OmpK-Omp22 Induce Protective Immunity Against

Cong Liu, Xingyun Wang, Yueling Zheng, Xingyue Gao, Jiahui Jin, Xing Cheng, Yunjiao He, Peng George Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Data-driven Atlas ofFrontiers in cellular and infection microbiology · 2026
    Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Cong LiuDepartment of Pharmacology, School of Medicine, Southern University of Science and Technology, Shenzhen 518000, China.
Xingyun WangDepartment of Pharmacology, School of Medicine, Southern University of Science and Technology, Shenzhen 518000, China.
Yueling ZhengDepartment of Pharmacology, School of Medicine, Southern University of Science and Technology, Shenzhen 518000, China.
Xingyue GaoDepartment of Pharmacology, School of Medicine, Southern University of Science and Technology, Shenzhen 518000, China.
Jiahui JinDepartment of Pharmacology, School of Medicine, Southern University of Science and Technology, Shenzhen 518000, China.
Xing ChengDepartment of Materials Science and Engineering, Southern University of Science and Technology, Shenzhen 518000, China.
Yunjiao HeDepartment of Pharmacology, School of Medicine, Southern University of Science and Technology, Shenzhen 518000, China.
Peng George WangDepartment of Pharmacology, School of Medicine, Southern University of Science and Technology, Shenzhen 518000, China.ORCID 0000-0003-3335-6794

Funding

National Key R&D Program of China,Shenzhen Science and Technology Innovation Commission, Key Project of Basic Research Special Project ,Natural Science Foundation of Guangdong Province, China,Shenzhen Overseas High-Level Talent 2023YFC3403200,JCYJ20220818100402004,2024A1515011286,KQTD20200909113758004
6 · The paper itself

Abstract

background

methodsIn this work, we developed two mRNA vaccines targeting SmpA-PLD and the fusion protein of outer membrane proteins OmpK and Omp22. The mRNA was encapsulated in LNP and administered to BALB/c mice. We evaluated humoral and cellular immune responses, bacterial burden, inflammation, and protective efficacy against

resultsThese mRNA vaccines triggered robust humoral and cellular immune responses in BALB/c mice, reduced bacterial burden and inflammation in sepsis models, and provided significant protection against

conclusionsOur findings demonstrate mRNA-LNP vaccine technology as a versatile and promising platform for the development of innovative therapeutics against

Indexed as

Acinetobacter baumanniibacterial infectionLNPmRNA vaccine

Identifiers

PMID40733741
PMCPMC12298923

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.